Our Pricing

Saxenda Pens: Complete UK Guide to Liraglutide Injection Treatment

Saxenda pens are pre-filled injection devices containing liraglutide 6mg/ml, prescribed for weight management in adults with a BMI of 30 or above, or 27 with weight-related conditions[1]. Each Saxenda pen delivers daily subcutaneous doses ranging from 0.6mg to 3.0mg, designed to reduce appetite and support clinically significant weight loss when combined with a reduced-calorie diet and increased physical activity[2]. At Cured Pharmacy, saxenda pens are available from £48.00 per pen following a free online consultation with our UK-registered prescribers.

How Saxenda Pens Work for Weight Loss

Saxenda pens contain liraglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 to regulate appetite and food intake[1]. When administered via the pre-filled pen device, liraglutide acts on areas of the brain involved in appetite regulation, helping patients feel fuller for longer and reducing overall caloric consumption[2]. Clinical trials demonstrated that patients using saxenda pens achieved an average weight loss of 8% of their initial body weight over 56 weeks, compared to 2.6% with placebo[3].

The saxenda pen mechanism supports weight management through multiple pathways: slowing gastric emptying to prolong satiety, reducing hunger signals in the hypothalamus, and decreasing the reward value of high-calorie foods[2]. Each pen is designed for ease of use, with a dose selector that clicks into place and a thin needle that makes daily injections straightforward for home administration. Patients typically start at 0.6mg daily and gradually increase to the maintenance dose of 3.0mg over five weeks to minimise gastrointestinal side effects[1].

Saxenda Pens vs Other GLP-1 Treatments

While saxenda pens require daily injections, newer GLP-1 treatments like semaglutide (Wegovy) offer weekly dosing schedules. However, saxenda pens remain a proven option for patients who prefer gradual dose titration and have established efficacy data from the SCALE clinical trial programme[3]. The daily dosing regimen of saxenda pens allows for more frequent dose adjustments under prescriber guidance, which some patients find beneficial during the initial treatment phase. At Cured Pharmacy, our clinical team assesses individual patient factors to recommend the most suitable weight loss treatment, whether saxenda pens or alternative GLP-1 therapies.

Saxenda Pens Dosing and Administration Guide

Each saxenda pen contains 18mg of liraglutide in 3ml solution, providing approximately 30 doses at the maximum 3.0mg daily maintenance level[1]. The recommended dose escalation schedule for saxenda pens begins at 0.6mg for week one, increasing by 0.6mg increments weekly until reaching 3.0mg by week five. This gradual titration minimises common side effects such as nausea and allows the body to adjust to the medication's appetite-suppressing effects[2].

Saxenda pens should be injected subcutaneously into the abdomen, thigh, or upper arm at any time of day, with or without meals, though maintaining a consistent daily schedule optimises treatment adherence[1]. The pen device is designed for single-patient use and should be stored in a refrigerator between 2°C and 8°C before first use, then can be kept at room temperature below 30°C for up to one month. Patients using saxenda pens should rotate injection sites to prevent lipodystrophy and always use a new needle for each injection to ensure sterility and proper dosing accuracy.

Clinical Efficacy of Saxenda Pens in Weight Management

The SCALE Obesity and Prediabetes trial, involving 3,731 participants, demonstrated that 63.2% of patients using saxenda pens achieved at least 5% weight loss compared to 27.1% on placebo after 56 weeks[3]. More impressively, 33.1% of saxenda pen users lost 10% or more of their initial body weight, versus just 10.6% in the placebo group. These results established saxenda pens as an effective pharmacological intervention for obesity when combined with lifestyle modifications[3].

Long-term data from saxenda pen clinical trials showed sustained weight loss maintenance over three years in patients who continued treatment, with significant improvements in cardiometabolic risk factors including blood pressure, lipid profiles, and glycaemic control[4]. Patients with prediabetes using saxenda pens experienced a 79% lower risk of developing type 2 diabetes compared to placebo over the study period[4]. At Cured Pharmacy, our prescribers review individual health profiles to determine if saxenda pens are appropriate based on BMI criteria, weight-related comorbidities, and previous weight loss attempts.

Real-World Effectiveness of Saxenda Pens

Post-marketing surveillance and real-world evidence studies confirm that saxenda pens deliver clinically meaningful weight loss outside controlled trial settings, though results vary based on adherence and lifestyle factors[5]. Patients who maintain consistent daily injections with saxenda pens and follow dietary guidance typically see noticeable weight reduction within 12-16 weeks. Treatment response is monitored through regular weight measurements, with guidelines recommending discontinuation if patients fail to lose at least 5% of initial weight after 12 weeks at the 3.0mg maintenance dose[1]. Our clinical team at Cured Pharmacy provides ongoing support to maximise treatment success with saxenda pens.

Saxenda Pens Side Effects and Safety Considerations

The most commonly reported side effects with saxenda pens are gastrointestinal in nature, including nausea (experienced by approximately 40% of patients), diarrhoea, constipation, and vomiting, particularly during the dose escalation phase[1]. These effects typically diminish as treatment continues and the body adapts to liraglutide. Eating smaller, more frequent meals and avoiding high-fat foods can help manage gastrointestinal symptoms while using saxenda pens[2].

Serious but rare risks associated with saxenda pens include pancreatitis, gallbladder disease, and increased heart rate[1]. Patients should be counselled to recognise signs of pancreatitis (severe abdominal pain radiating to the back) and seek immediate medical attention if symptoms occur. Saxenda pens are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2[1]. Our prescribers at Cured Pharmacy conduct thorough medical history reviews before approving saxenda pens to ensure patient safety and appropriate use.

Cost and Availability of Saxenda Pens in the UK

Saxenda pens are available from Cured Pharmacy at £48.00 per pen, representing competitive UK pricing for this prescription weight loss treatment. New patients can Save £20 on their first order using code Weightlossnew, making the initial pen just £48.00. Each pen lasts approximately 6 days at the maximum 3.0mg dose, or longer during the titration phase when lower doses are used[1].

While saxenda pens are not routinely available on NHS prescription due to funding restrictions in most areas, private prescription access through registered online pharmacies like Cured Pharmacy ensures availability for eligible patients. All purchases of saxenda pens require completion of a free online consultation with our UK-registered prescribers, who assess suitability based on BMI, medical history, and contraindications. Treatment is dispensed from our GPhC-registered pharmacy with discreet packaging and next-day delivery options available across the UK.

Saxenda Pens Supply and Prescription Process

Obtaining saxenda pens through Cured Pharmacy involves a streamlined three-step process: complete the online medical questionnaire (typically under 3 minutes), receive prescriber review and approval within hours, and have saxenda pens dispensed and shipped discreetly to your address. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services to ensure compliance with UK pharmacy regulations and patient safety standards. Repeat prescriptions for saxenda pens can be arranged through your online account, with regular clinical check-ins to monitor progress and adjust treatment as needed.

Maximising Weight Loss Results with Saxenda Pens

Achieving optimal outcomes with saxenda pens requires integration of the medication into a comprehensive weight management programme that includes dietary modification, increased physical activity, and behavioural strategies[2]. Clinical trial participants using saxenda pens who adhered to a 500-calorie daily deficit and engaged in at least 150 minutes of moderate exercise weekly achieved significantly greater weight loss than those relying on medication alone[3].

Patients using saxenda pens should maintain a food diary to track caloric intake, plan balanced meals rich in protein and fibre to enhance satiety, and establish regular eating patterns that align with the medication's appetite-suppressing effects[5]. Setting realistic weight loss goals of 0.5-1kg per week helps maintain motivation during saxenda pen treatment. Our clinical team at Cured Pharmacy provides evidence-based guidance on lifestyle modifications that complement saxenda pens, supporting sustainable weight management beyond the treatment period. Regular weight monitoring and clinical follow-up every 12 weeks ensures treatment effectiveness and allows for timely adjustments to the weight loss plan.

Scientific References

1. Electronic Medicines Compendium. (2023). Saxenda 6 mg/ml solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk.
2. Lean, M. E., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014). Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. International Journal of Obesity, 38(5), 689-697.
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
4. le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C., Van Gaal, L., Ortiz, R. V., Wilding, J. P., Skjøth, T. V., Manning, L. S., & Pi-Sunyer, X. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes. The Lancet, 389(10077), 1399-1409.
5. Wilding, J. P., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., & Kushner, R. F. (2021). Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism, 24(8), 1553-1564.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.